2021 Volume 28 Issue 4 Pages 43-48
Background: Medical practitioners should manage chronic pain while trying to minimize adverse events induced by the treatment. The aim of this study was to investigate the clinical adverse events of mirogabalin (MGB) switching from pregabalin (PGB) in chronic pain management. Methods: We administered MGB at 2.5–5 mg, lower than the recommended dosage, for chronic neuropathic pain patients switching from PGB once the dose was lower than or equal to 150 mg, and prospectively assessed adverse events at 2, 4, 8, 12, 24 weeks. MGB was increased gradually until adequate pain relief was achieved. Results: Of 257 patients, 87 cases (33.9％) ceased MGB due to adverse events. The most frequent side effects observed were somnolence and dizziness. These results were mostly the same as mirogabalin phase III studies. No withdrawal symptoms or pain exacerbation were observed in association with PGB discontinuation. Conclusions: MGB would be safer to administer with low-dose and increase slowly when switching from PGB of lower than or equal to 150 mg.
